98 related articles for article (PubMed ID: 25367955)
1. Loss of PRC2 function promotes MPNST pathogenesis.
Cancer Discov; 2014 Nov; 4(11):OF14. PubMed ID: 25367955
[TBL] [Abstract][Full Text] [Related]
2. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.
Lee W; Teckie S; Wiesner T; Ran L; Prieto Granada CN; Lin M; Zhu S; Cao Z; Liang Y; Sboner A; Tap WD; Fletcher JA; Huberman KH; Qin LX; Viale A; Singer S; Zheng D; Berger MF; Chen Y; Antonescu CR; Chi P
Nat Genet; 2014 Nov; 46(11):1227-32. PubMed ID: 25240281
[TBL] [Abstract][Full Text] [Related]
3. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
[TBL] [Abstract][Full Text] [Related]
4. The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor.
Zhang X; Murray B; Mo G; Shern JF
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32182803
[TBL] [Abstract][Full Text] [Related]
5. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state.
Kochat V; Raman AT; Landers SM; Tang M; Schulz J; Terranova C; Landry JP; Bhalla AD; Beird HC; Wu CC; Jiang Y; Mao X; Lazcano R; Gite S; Ingram DR; Yi M; Zhang J; Keung EZ; Scally CP; Roland CL; Hunt KK; Feig BW; Futreal PA; Hwu P; Wang WL; Lazar AJ; Slopis JM; Wilson-Robles H; Wiener DJ; McCutcheon IE; Wustefeld-Janssens B; Rai K; Torres KE
Acta Neuropathol; 2021 Sep; 142(3):565-590. PubMed ID: 34283254
[TBL] [Abstract][Full Text] [Related]
6. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
[No Abstract] [Full Text] [Related]
7. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
8. Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics.
Sugita S; Aoyama T; Emori M; Kido T; Takenami T; Sakuraba K; Terai K; Sugawara T; Tsujiwaki M; Hasegawa T
Diagn Pathol; 2021 Aug; 16(1):79. PubMed ID: 34461930
[TBL] [Abstract][Full Text] [Related]
9. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.
Spurlock G; Knight SJ; Thomas N; Kiehl TR; Guha A; Upadhyaya M
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1869-80. PubMed ID: 20229272
[TBL] [Abstract][Full Text] [Related]
10. Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs).
Upadhyaya M; Kluwe L; Spurlock G; Monem B; Majounie E; Mantripragada K; Ruggieri M; Chuzhanova N; Evans DG; Ferner R; Thomas N; Guha A; Mautner V
Hum Mutat; 2008 Jan; 29(1):74-82. PubMed ID: 17960768
[TBL] [Abstract][Full Text] [Related]
11. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.
De Raedt T; Beert E; Pasmant E; Luscan A; Brems H; Ortonne N; Helin K; Hornick JL; Mautner V; Kehrer-Sawatzki H; Clapp W; Bradner J; Vidaud M; Upadhyaya M; Legius E; Cichowski K
Nature; 2014 Oct; 514(7521):247-51. PubMed ID: 25119042
[TBL] [Abstract][Full Text] [Related]
12.
Oppel F; Ki DH; Zimmerman MW; Ross KN; Tao T; Shi H; He S; Aster JC; Look AT
Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32651197
[TBL] [Abstract][Full Text] [Related]
13. A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A/p16: a case report showing progression from a neurofibroma to a high-grade MPNST.
Tajima S; Koda K
Int J Clin Exp Pathol; 2015; 8(5):5113-20. PubMed ID: 26191206
[TBL] [Abstract][Full Text] [Related]
14. From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor.
Lemberg KM; Wang J; Pratilas CA
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32599735
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors.
Endo M; Kobayashi C; Setsu N; Takahashi Y; Kohashi K; Yamamoto H; Tamiya S; Matsuda S; Iwamoto Y; Tsuneyoshi M; Oda Y
Clin Cancer Res; 2011 Jun; 17(11):3771-82. PubMed ID: 21262917
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.
Danis E; Yamauchi T; Echanique K; Haladyna J; Kalkur R; Riedel S; Zhu N; Xie H; Bernt KM; Orkin SH; Armstrong SA; Neff T
Exp Hematol; 2015 Nov; 43(11):930-935.e6. PubMed ID: 26118502
[TBL] [Abstract][Full Text] [Related]
17. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.
Beert E; Brems H; Daniëls B; De Wever I; Van Calenbergh F; Schoenaers J; Debiec-Rychter M; Gevaert O; De Raedt T; Van Den Bruel A; de Ravel T; Cichowski K; Kluwe L; Mautner V; Sciot R; Legius E
Genes Chromosomes Cancer; 2011 Dec; 50(12):1021-32. PubMed ID: 21987445
[TBL] [Abstract][Full Text] [Related]
18. Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation.
Rhodes SD; He Y; Smith A; Jiang L; Lu Q; Mund J; Li X; Bessler W; Qian S; Dyer W; Sandusky GE; Horvai AE; Armstrong AE; Clapp DW
Hum Mol Genet; 2019 Aug; 28(16):2752-2762. PubMed ID: 31091306
[TBL] [Abstract][Full Text] [Related]
19. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
[TBL] [Abstract][Full Text] [Related]
20. Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms.
Reuss DE; Habel A; Hagenlocher C; Mucha J; Ackermann U; Tessmer C; Meyer J; Capper D; Moldenhauer G; Mautner V; Frappart PO; Schittenhelm J; Hartmann C; Hagel C; Katenkamp K; Petersen I; Mechtersheimer G; von Deimling A
Acta Neuropathol; 2014 Apr; 127(4):565-72. PubMed ID: 24464231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
